In a study published online in The Lancet Infectious Diseases, investigators revealed promising results of a phase I/II trial of a new Lyme disease vaccine.
Lyme disease is caused by the Borrelia species of tick across the USA, Europe and Asia. No human vaccine for Lyme disease currently exists – although the history of the Lyme disease vaccine LYMERix is nicely detailed here.
This novel Lyme disease vaccine contained epitopes from Borrelia species outer surface protein A (OspA) serotypes. Investigators examined the safety and immunogenicity of the vaccine in 300 trial participants, assigning half the participants to receive the adjuvanted vaccines and half to receive the non-adjuvanted vaccines. All doses and formulations induced substantial mean IgG antibody titres after the first three vaccinations and booster immunisations.
What do you think? You can leave a comment in the box below, or on LinkedIn group discussion.
If you want to know more about strategy and innovation in vaccines, you might be interested in attending theWorld Vaccine Congress Asia 2013, 17-20 June 2013, Singapore. Want more from Vaccine Nation? Sign up to our newsletter for free here.